Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and morbidity and these rates have not significantly changed in the recent years. None of the currently approved AHF therapies have been demonstrated to improve clinical outcomes; therefore, the main focus of current treatment of AHF remains symptomatic relief. Here we show how AHF is currently being treated and what drives the choice of pharmacotherapy for AHF patients. We reveal how and when AHF agents are being used, from the initiation of therapy, typically with loop diuretics, through to further lines of treatment.
Questions answered in this report: